Mayo Clinic
The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.
Inclusion Criteria * Adults aged \> 18 years (All women of childbearing potential undergo pregnancy testing prior to THA as per our institutional protocol) * Written informed consent * Patients undergoing primary THA diagnosis of end-stage osteoarthritis * Patients receiving spinal anesthesia * Patients being discharged on postoperative day 1 Exclusion Criteria * Patients with a TXA allergy * Patients undergoing revision procedures * Patients undergoing primary THA for a diagnosis other than end-stage osteoarthritis * Patients receiving general anesthesia * Patients being discharged on the…
Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3
Arctuva estimate
Verify or correct the compensation shown for this listing.